To date three serum glycoproteins including cancer antigen (CA 15–3) and CA 27–29 that encoded by MUC1 gene, and carcinoembryonic antigen (CEA) are regarded as traditional biomarkers used for clinically detection and monitor breast cancer occurrence and recurrence through serum glycoprotein immunoassays [49, 81, 128]. This evidence concerns the gene MUC1 and breast cancer.